Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop
growing or die. Colony-stimulating factors such as sargramostim may increase the number of
immune cells found in bone marrow or peripheral blood and may help a person's immune system
recover from the side effects of chemotherapy. Phase I trial to study the effectiveness of
bryostatin 1 combined with sargramostim in treating patients who have refractory myeloid
cancer